Journal of pediatric gastroenterology and nutrition · 2026
Altered T cell immune profile and its prognostic implications in children with portal hypertension: A pilot study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Si Tengfei, Yu Huihong, Tucker Bethany, Dato Fabiola Di, Shao Qing, Luo Xuan, Chan Cody, Kane Pauline, Lewis Dylan, Kyrana Eirini, Ma Yun, Grammatikopoulos Tassos
Аннотация
OBJECTIVES: Immune dysregulation in paediatric portal hypertension (PHT) is poorly understood. We aimed to characterise T cell phenotype and function and circulating immune mediators in children with PHT according to disease aetiology.
METHODS: Forty-four children with PHT (27 chronic liver disease [CLD]-related and 17 portal vein thrombosis [PVT]-related) and 15 healthy controls were prospectively enrolled. Peripheral and portal blood samples were analysed using multiparameter flow cytometry and ELISA to assess T cell subsets, chemokine receptors, cytokines and soluble immune markers. Analyses examined group differences and correlations with liver stiffness and bleeding history.
RESULTS: PHT was associated with reduced circulating T cells, altered immune phenotypes and impaired effector function. CLD-related PHT exhibited a pronounced pro-inflammatory profile, with elevated IFN-γ, TNF-α, MMP7 and soluble PD-L1 and increased CD39 and PD-1. PVT-related PHT showed relatively preserved liver function and milder systemic inflammation but altered T cell trafficking, characterised by increased CCR4 and reduced CXCR3 expression. Elevated CXCL9 correlated with CXCR3 expression. T cells in the portal circulation displayed reduced cytokine production and cytotoxicity, suggesting functional adaptation within the hepatic microenvironment. Liver stiffness correlated positively with pro-inflammatory cytokines and immune-regulatory markers.
CONCLUSIONS: Paediatric PHT is characterised by aetiology-specific T cell dysregulation. CLD-related PHT predominantly features chronic inflammation and T cell exhaustion, whereas PVT-related PHT shows a milder inflammatory phenotype with altered T cell trafficking. These findings provide mechanistic insights and identify candidate immune signatures requiring validation in larger, aetiology-specific cohorts.
METHODS: Forty-four children with PHT (27 chronic liver disease [CLD]-related and 17 portal vein thrombosis [PVT]-related) and 15 healthy controls were prospectively enrolled. Peripheral and portal blood samples were analysed using multiparameter flow cytometry and ELISA to assess T cell subsets, chemokine receptors, cytokines and soluble immune markers. Analyses examined group differences and correlations with liver stiffness and bleeding history.
RESULTS: PHT was associated with reduced circulating T cells, altered immune phenotypes and impaired effector function. CLD-related PHT exhibited a pronounced pro-inflammatory profile, with elevated IFN-γ, TNF-α, MMP7 and soluble PD-L1 and increased CD39 and PD-1. PVT-related PHT showed relatively preserved liver function and milder systemic inflammation but altered T cell trafficking, characterised by increased CCR4 and reduced CXCR3 expression. Elevated CXCL9 correlated with CXCR3 expression. T cells in the portal circulation displayed reduced cytokine production and cytotoxicity, suggesting functional adaptation within the hepatic microenvironment. Liver stiffness correlated positively with pro-inflammatory cytokines and immune-regulatory markers.
CONCLUSIONS: Paediatric PHT is characterised by aetiology-specific T cell dysregulation. CLD-related PHT predominantly features chronic inflammation and T cell exhaustion, whereas PVT-related PHT shows a milder inflammatory phenotype with altered T cell trafficking. These findings provide mechanistic insights and identify candidate immune signatures requiring validation in larger, aetiology-specific cohorts.